In a landmark development for oncology, a pioneering clinical trial has revealed that a short, targeted course of immunotherapy administered prior to surgery can dramatically improve long-term outcomes for patients with specific forms of colorectal cancer. The NEOPRISM-CRC study, led by researchers at University College London (UCL) and University College London Hospitals (UCLH), has demonstrated that replacing traditional post-surgical chemotherapy with just nine weeks of the immunotherapy drug pembrolizumab results in profound, lasting remission.
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego suggests that this "neoadjuvant" approach—treating the disease before it is surgically removed—may represent a paradigm shift in how high-risk bowel cancers are managed. For patients, the results are nothing short of life-changing: after nearly three years of follow-up, not a single participant in the trial has experienced a cancer recurrence.
The NEOPRISM-CRC Study: Redefining Standards of Care
The traditional standard of care for stage two and three colorectal cancer has long been a demanding regimen: surgery followed by several months of grueling chemotherapy. While effective for many, this approach carries significant side effects and does not guarantee that the cancer will not return. Statistics indicate that approximately 25% of patients undergoing this standard treatment pathway see their cancer return within three years.
The NEOPRISM-CRC trial sought to challenge this model by focusing on a specific genetic subtype of the disease known as "MMR-deficient" (mismatch repair deficient) or "MSI-high" (microsatellite instability-high) colorectal cancer. This subtype, which accounts for roughly 10% to 15% of such cases—equating to between 2,000 and 3,000 patients annually in the UK—has historically shown a unique sensitivity to immunotherapy.
In the study, 32 participants received pembrolizumab for nine weeks before undergoing surgery. The results were immediate and startling. Early findings showed that 59% of patients had no detectable cancer remaining by the time they reached the operating theater. Today, with the benefit of 33 months of follow-up data, the success rate is even more compelling: zero recurrences among the entire study cohort.
A Chronology of Success: From Diagnosis to Remission
To understand the impact of the NEOPRISM-CRC trial, one must look at the timeline of the patient experience. For participants like 73-year-old Christopher Burston, the journey began with a routine screening that identified blood in his stool—a common but often overlooked warning sign.
February 2023: The Diagnosis
Following a colonoscopy, Mr. Burston was diagnosed with stage three colorectal cancer. The psychological weight of such a diagnosis is immense, but he was quickly offered a lifeline in the form of the NEOPRISM trial.
March–May 2023: The Immunotherapy Phase
Rather than undergoing immediate surgery followed by the uncertainty of chemotherapy, Mr. Burston began a nine-week course of pembrolizumab. The immunotherapy worked with remarkable speed, acting as a biological "reset" button that targeted the tumor cells directly.
May 2023: The Surgical Intervention
By the time Mr. Burston reached the operating room, his surgical team was met with an unexpected result: the tumor, which had previously been substantial in size, had effectively "melted away." The immunotherapy had performed the heavy lifting, rendering the subsequent surgery far less invasive than it otherwise would have been.
2023–2026: The Long-Term Follow-Up
In the years since his surgery, Mr. Burston has remained cancer-free. His experience mirrors that of his peers in the trial, all of whom have avoided the standard post-operative chemotherapy regimen that many cancer patients dread due to its systemic toxicity.
The Science of Success: Why Immunotherapy Works
The efficacy of the NEOPRISM-CRC approach lies in the specific biology of MMR-deficient tumors. These tumors possess a high number of genetic mutations, which makes them highly visible to the immune system. Pembrolizumab acts as an "immune checkpoint inhibitor," effectively taking the brakes off the body’s natural defense mechanisms and allowing T-cells to identify and destroy cancer cells with precision.
Personalized Blood Tests as Predictive Tools
A significant component of the research involved the development of personalized blood tests—often referred to as liquid biopsies—to track the presence of circulating tumor DNA (ctDNA). By analyzing blood samples throughout the nine-week treatment window, researchers were able to predict which patients were responding most favorably.
The correlation between the disappearance of ctDNA from the bloodstream and the long-term clinical outcome was near-perfect. This discovery provides a vital tool for the future: the ability to "triage" patients. Those whose blood tests show a rapid clearance of tumor DNA may eventually require less surgery or fewer post-operative interventions, while those who show resistance can be identified earlier for more aggressive, alternative therapies.
Official Perspectives: Experts Weigh In
The findings from the UCL and UCLH team have sent waves of optimism through the oncology community. Dr. Kai-Keen Shiu, Chief Investigator of the trial and a Consultant Medical Oncologist at UCLH, emphasized the safety and transformative potential of this protocol.
"Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging," Dr. Shiu stated. "It strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers."
Dr. Shiu highlighted that the future of cancer care lies in this type of tailored approach. "What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling. These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy versus patients at higher risk of disease progression."
Professor Marnix Jansen of the UCL Cancer Institute added that the study has provided more than just clinical data; it has offered deep biological insights into why immunotherapy works so efficiently in this specific cohort, validating the "durability" of the immune response.
Implications for the Future of Cancer Care
The implications of the NEOPRISM-CRC trial extend far beyond the 32 patients involved in the study. As bowel cancer continues to be the fourth most common cancer in the UK, with a worrying rise in diagnoses among adults under the age of 50, the need for more effective, less toxic treatments is critical.
1. Shift in Standard Protocols
If these results are replicated in larger, phase III trials, they could lead to a global shift in standard protocols for MMR-deficient colorectal cancer. By prioritizing immunotherapy over chemotherapy, the medical community could spare thousands of patients from the debilitating side effects of traditional chemo, while simultaneously improving survival rates.
2. Economic and Quality-of-Life Benefits
Beyond the survival statistics, the quality-of-life benefits are substantial. Patients who avoid chemotherapy maintain better physical health and avoid the long-term complications associated with systemic cytotoxic treatments. Furthermore, the ability to use predictive blood tests could optimize hospital resources, ensuring that intensive follow-up care is directed toward those who truly need it.
3. Early Detection and Precision Medicine
The trial underscores the vital importance of genetic profiling at the point of diagnosis. If every colorectal cancer patient were tested for the MMR/MSI status early on, a greater number of patients could be funneled into these targeted immunotherapy trials, potentially saving more lives.
Conclusion: A New Horizon
The success of the NEOPRISM-CRC study represents a beacon of hope for thousands of families affected by colorectal cancer. While the trial was relatively small, its results are statistically significant and biologically robust. By combining cutting-edge immunotherapy with the precision of personalized blood testing, the researchers at UCL and UCLH have provided a blueprint for the future of oncology.
As we look toward the wider integration of these methods into clinical practice, the focus remains on the patients—like Christopher Burston—who are no longer defined by their cancer, but by their return to a full and healthy life. The message from the 2026 AACR meeting is clear: we are moving closer to an era where cancer is not just treated, but effectively and permanently managed through the power of the body’s own immune system.
